Parathyroid-specific epidermal growth factor-receptor inactivation prevents uremia-induced parathyroid hyperplasia in mice

Nephrology Dialysis Transplantation

Volumn 30, Issue 3, 2015, Pages 434-440

  Arcidiacono, Maria Vittoria ^a,b,c   Yang, Jing ^a   Fernandez, Elvira ^b,c   Dusso, Adriana ^a,b,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF LLEIDA   (Spain)

^c HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

Author keywords

calcium; phosphate; secondary hyperparathyroidism; transforming growth factor alpha; vitamin D receptor

Indexed keywords

CALCIUM; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR 23; HETERODIMER; MUTANT PROTEIN; PARATHYROID HORMONE; PHOSPHATE; TRANSFORMING GROWTH FACTOR ALPHA; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; EGFR PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; FVB/N MOUSE; GENOTYPE; KIDNEY MASS; MORPHOLOGY; MOUSE; MULTIPLE ORGAN FAILURE; NONHUMAN; PARATHYROID DISEASE; PARATHYROID GLAND; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HYPERPLASIA; PATHOGENESIS; PHENOTYPE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY SEQUENCE; TRANSGENIC MOUSE; UREA NITROGEN BLOOD LEVEL; UREMIA; WILD TYPE MOUSE; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPLICATION; GENETICS; HUMAN; HYPERPARATHYROIDISM, SECONDARY; HYPERPLASIA; IN SITU HYBRIDIZATION; MALE; METABOLISM; MUTATION; PATHOLOGY; RAT; RENAL INSUFFICIENCY, CHRONIC;

ANIMALS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPERPLASIA; IN SITU HYBRIDIZATION; MALE; MICE; MICE, TRANSGENIC; MUTATION; PARATHYROID GLANDS; PARATHYROID HORMONE; PROMOTER REGIONS, GENETIC; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CALCITRIOL; RENAL INSUFFICIENCY, CHRONIC; UREMIA;

EID: 84924421161     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu318     Document Type: Article

References (22)

1. Kidney Disease: Improving Global Outcomes CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; 113: S1-130
2. Silver J, Rodriguez M, Slatopolsky E. FGF23 and PTH-double agents at the heart of CKD. Nephrol Dial Transplant 2012; 27: 1715-1720
3. Silver J, Naveh-Many T. FGF-23 and secondary hyperparathyroidism in chronic kidney disease. Nat Rev Nephrol 2013; 9: 641-649
4. Arcidiacono MV, Sato T, Alvarez-Hernandez D et al. EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease. J Am Soc Nephrol 2008; 19: 310-320
5. Cozzolino M, Lu Y, Sato T et al. A critical role for enhanced TGF-alpha and EGFR expression in the initiation of parathyroid hyperplasia in experimental kidney disease. Am J Physiol Renal Physiol 2005; 289: F1096-F1102
6. Lautrette A, Li S, Alili R et al. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med 2005; 11: 867-874
7. Melenhorst WB, Visser L, Timmer A et al. ADAM17 upregulation in human renal disease: a role in modulating TGF-alpha availability? Am J Physiol Renal Physiol 2009; 297: F781-F790
8. Terzi F, Burtin M, Hekmati M et al. Targeted expression of a dominantnegative EGF-R in the kidney reduces tubulo-interstitial lesions after renal injury. J Clin Invest 2000; 106: 225-234
9. Murillas R, Larcher F, Conti CJ et al. Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. EMBO J 1995; 14: 5216-5223
10. Imanishi Y, Hosokawa Y, Yoshimoto K et al. Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice. J Clin Invest 2001; 107: 1093-1102
11. Schrick JJ, Dickinson ME, Hogan BL et al. Molecular and phenotypic characterization of a new mouse insertional mutation that causes a defect in the distal vertebrae of the spine. Genetics 1995; 140: 1061-1067
12. Wang Q, Palnitkar S, Parfitt AM. Parathyroid cell proliferation in the rat: effect of age and of phosphate administration and recovery. Endocrinology 1996; 137: 4558-4562
13. Wang Q, Palnitkar S, Parfitt AM. The basal rate of cell proliferation in normal human parathyroid tissue: implications for the pathogenesis of hyperparathyroidism. Clin Endocrinol (Oxf) 1997; 46: 343-349
14. Parfitt AM. The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int 1997; 52: 3-9
15. Komaba H, Goto S, Fujii H et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 2010; 77: 232-238
16. Galitzer H, Ben-Dov IZ, Silver J et al. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 2010; 77: 211-218
17. Canalejo R, Canalejo A, Martinez-Moreno JM et al. FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol 2010; 21: 1125-1135
18. Olauson H, Lindberg K, Amin R et al. Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion. PLoS Genet 2013; 9: e1003975
19. Gogusev J, Duchambon P, Stoermann-Chopard C et al. De novo expression of transforming growth factor-alpha in parathyroid gland tissue of patients with primary or secondary uraemic hyperparathyroidism. Nephrol Dial Transplant 1996; 11: 2155-2162
20. Arcidiacono MV, Cozzolino M, Spiegel N et al. Activator protein 2alpha mediates parathyroid TGF-alpha self-induction in secondary hyperparathyroidism. J Am Soc Nephrol 2008; 19: 1919-1928
21. Forster RE, Jurutka PW, Hsieh JC et al. Vitamin D receptor controls expression of the anti-aging klotho gene in mouse and human renal cells. Biochem Biophys Res Commun 2011; 414: 557-562
22. Peschon JJ, Slack JL, Reddy P et al. An essential role for ectodomain shedding in mammalian development. Science 1998; 282: 1281-1284